Physician profile
Elvis Alfonso
NPI 1477739233
$881.75
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $253 · 2021: $205.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $308.32 | 2019-2021 | |
| Therapeuticsmd, INC. | $226.05 | 2019-2020 | |
| Lupin INC. | $111.33 | 2019-2021 | |
| Abbvie INC. | $45.46 | 2021 | |
| Myovant Sciences INC. | $44.52 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.16 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $27.73 | 2019-2020 | |
| Duchesnay USA Incorporated | $23.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.20 | 2021 | |
| Mylan Pharmaceuticals INC. | $19.83 | 2020 | |
| Hologic Sales and Service, LLC | $12.70 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elvis Alfonso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.